References in periodicals archive ?
Progressive cardiac fibrosis interferes with the cardiac pump function and increases the risk of death.
The new PARADYM[TM] device with its sonR[TM] functionality is designed to measure and evaluate the performance of the cardiac pump, and to adapt the CRT settings to the patients' cardiac status automatically and recurrently during patients' everyday life.
These two contracts continue this tradition, utilizing different but exciting cutting edge therapies for the treatment of patients with poor cardiac pump function.
Director of the Innovative Ventricular Assist System (IVAS) Program at Cleveland Clinic, who will discuss the state-of-the-art cardiac pump for use in patients with terminal heart failure that was developed at Cleveland Clinic.